Clinuvel Pharmaceuticals Gestion

Gestion contrôle des critères 2/4

Le PDG Clinuvel Pharmaceuticals est Philippe Wolgen, nommé en Nov2005, a un mandat de 19.08 ans. La rémunération annuelle totale est A$ 3.74M, composée du salaire de 47.2% et des bonus 52.8%, y compris les actions et options de la société. détient directement 6.86% des actions de la société, d'une valeur de A$ 45.08M. La durée moyenne de mandat de l'équipe de direction et du conseil d'administration est respectivement 0.9 ans et 5 ans.

Informations clés

Philippe Wolgen

Directeur général

AU$3.7m

Rémunération totale

Pourcentage du salaire du PDG	47.2%
Durée du mandat du directeur général	19yrs
Propriété du PDG	6.9%
Durée moyenne d'occupation des postes de direction	less than a year
Durée moyenne du mandat des membres du conseil d'administration	5yrs

Mises à jour récentes de la gestion

Increases to Clinuvel Pharmaceuticals Limited's (ASX:CUV) CEO Compensation Might Cool off for now

Oct 20

Recent updates

If EPS Growth Is Important To You, Clinuvel Pharmaceuticals (ASX:CUV) Presents An Opportunity

Aug 11

An Intrinsic Calculation For Clinuvel Pharmaceuticals Limited (ASX:CUV) Suggests It's 41% Undervalued

Nov 18

Increases to Clinuvel Pharmaceuticals Limited's (ASX:CUV) CEO Compensation Might Cool off for now

Oct 20

Is Clinuvel Pharmaceuticals Limited (ASX:CUV) Trading At A 21% Discount?

Jul 30

Clinuvel Pharmaceuticals Limited (ASX:CUV) Shares Could Be 27% Below Their Intrinsic Value Estimate

Feb 27

Does Clinuvel Pharmaceuticals (ASX:CUV) Deserve A Spot On Your Watchlist?

Dec 14

This Is The Reason Why We Think Clinuvel Pharmaceuticals Limited's (ASX:CUV) CEO Might Be Underpaid

Nov 03

A Look At The Fair Value Of Clinuvel Pharmaceuticals Limited (ASX:CUV)

Sep 23

Here's Why I Think Clinuvel Pharmaceuticals (ASX:CUV) Might Deserve Your Attention Today

Jul 23

With EPS Growth And More, Clinuvel Pharmaceuticals (ASX:CUV) Is Interesting

Apr 10

Have Insiders Sold Clinuvel Pharmaceuticals Limited (ASX:CUV) Shares Recently?

Mar 06

Earnings Miss: Clinuvel Pharmaceuticals Limited Missed EPS By 41% And Analysts Are Revising Their Forecasts

Feb 27

What Is The Ownership Structure Like For Clinuvel Pharmaceuticals Limited (ASX:CUV)?

Feb 20

Clinuvel Pharmaceuticals (ASX:CUV) Shareholders Have Enjoyed A Whopping 648% Share Price Gain

Feb 01

Estimating The Fair Value Of Clinuvel Pharmaceuticals Limited (ASX:CUV)

Jan 14

We Wouldn't Rely On Clinuvel Pharmaceuticals's (ASX:CUV) Statutory Earnings As A Guide

Dec 28

Clinuvel Pharmaceuticals Limited's (ASX:CUV) Stock's On An Uptrend: Are Strong Financials Guiding The Market?

Dec 10

What You Need To Know About Clinuvel Pharmaceuticals Limited's (ASX:CUV) Investor Composition

Nov 21

Analyse de la rémunération des PDG

Comment la rémunération de Philippe Wolgen a-t-elle évolué par rapport aux bénéfices de Clinuvel Pharmaceuticals?
Date	Rémunération totale	Salaire	Bénéfices de l'entreprise
Jun 30 2024	AU$4m	AU$2m	AU$36m
Mar 31 2024	n/a	n/a	AU$33m
Dec 31 2023	n/a	n/a	AU$30m
Sep 30 2023	n/a	n/a	AU$30m
Jun 30 2023	AU$6m	AU$2m	AU$31m
Mar 31 2023	n/a	n/a	AU$29m
Dec 31 2022	n/a	n/a	AU$26m
Sep 30 2022	n/a	n/a	AU$24m
Jun 30 2022	AU$7m	AU$1m	AU$21m
Mar 31 2022	n/a	n/a	AU$22m
Dec 31 2021	n/a	n/a	AU$24m
Sep 30 2021	n/a	n/a	AU$24m
Jun 30 2021	AU$5m	AU$2m	AU$25m
Mar 31 2021	n/a	n/a	AU$23m
Dec 31 2020	n/a	n/a	AU$21m
Sep 30 2020	n/a	n/a	AU$18m
Jun 30 2020	AU$3m	AU$2m	AU$15m
Mar 31 2020	n/a	n/a	AU$15m
Dec 31 2019	n/a	n/a	AU$15m
Sep 30 2019	n/a	n/a	AU$16m
Jun 30 2019	AU$1m	AU$894k	AU$18m
Mar 31 2019	n/a	n/a	AU$17m
Dec 31 2018	n/a	n/a	AU$16m
Sep 30 2018	n/a	n/a	AU$15m
Jun 30 2018	AU$2m	AU$818k	AU$13m

Rémunération vs marché: La rémunération totale de Philippe ($USD 2.44M ) est supérieure à la moyenne des entreprises de taille similaire sur le marché Australian ($USD 910.58K ).

Rémunération et revenus: La rémunération de Philippe a été cohérente avec les performances de l'entreprise au cours de l'année écoulée.

PDG

Philippe Wolgen (61 yo)

19yrs

Titularisation

AU$3,742,412

Compensation

Dr. Philippe Jacques Wolgen, MBA, M.D., has been the Chief Executive Officer and Managing Director of Clinuvel Pharmaceuticals Limited since November 28, 2005 to lead the corporate turnaround of the Group....

Équipe de direction

Nom	Position	Titularisation	Compensation	Propriété
Philippe Wolgen	CEO, MD & Director	19yrs	AU$3.74m	6.86% A$ 45.9m
Dennis Wright	Chief Scientific Officer	12.2yrs	AU$782.61k	0.38% A$ 2.5m
Peter Vaughan	Chief Financial Officer	less than a year	pas de données	pas de données
Lachlan Hay	Chief Operations Officer	no data	pas de données	pas de données
Malcolm Bull	Head of Australian Operations & Investor Relations	no data	pas de données	pas de données
Rose Quadbeck-Diel	Senior Vice President of Regulatory Affairs	less than a year	pas de données	pas de données
Azza Hamila	Head of Quality Assurance & Drug Safety	less than a year	pas de données	pas de données
Claire Newstead-Sinclair	Company Secretary	less than a year	pas de données	pas de données

0.9yrs

Durée moyenne de l'emploi

Gestion expérimentée: L'équipe de direction de CUV n'est pas considérée comme expérimentée (ancienneté moyenne 0.9 ans), ce qui suggère une nouvelle équipe.

Membres du conseil d'administration

Nom	Position	Titularisation	Compensation	Propriété
Philippe Wolgen	CEO, MD & Director	19.1yrs	AU$3.74m	6.86% A$ 45.9m
Pearl Grimes	Non-Executive Director	less than a year	pas de données	pas de données
Matthew Pringle	Non-Executive Director	less than a year	pas de données	pas de données
Susan Smith	Non-Executive Director	5.2yrs	AU$80.00k	0.00084% A$ 5.6k
Jeffrey Rosenfeld	Non-Executive Chairman	5yrs	AU$91.67k	0.0063% A$ 42.2k
Karen Agersborg	Non-Executive Director	6.8yrs	AU$75.00k	0.028% A$ 185.4k
Guy van Dievoet	Non-Executive Director	less than a year	pas de données	pas de données

5.0yrs

Durée moyenne de l'emploi

Conseil d'administration expérimenté: Les membres du conseil d'administration de CUV sont considérés comme expérimentés (ancienneté moyenne 5 ans).

Clinuvel Pharmaceuticals Gestion

Gestion contrôle des critères 2/4

Informations clés

Mises à jour récentes de la gestion

Clinuvel Pharmaceuticals Limited, Annual General Meeting, Oct 16, 2024

Clinuvel Pharmaceuticals Limited Announces Change of Company Secretary

Clinuvel Pharmaceuticals Limited Announces Board Changes

Clinuvel Pharmaceuticals Limited, Annual General Meeting, Oct 31, 2023

No independent directors

Increases to Clinuvel Pharmaceuticals Limited's (ASX:CUV) CEO Compensation Might Cool off for now

Recent updates

CLINUVEL Files Canadian New Drug Submission for SCENESSE® in EPP

Clinuvel Pharmaceuticals Limited, Annual General Meeting, Oct 16, 2024

Dividend of AU$0.05 announced

Full year 2024 earnings: EPS and revenues exceed analyst expectations

Investor sentiment improves as stock rises 17%

Clinuvel Pharmaceuticals Limited to Report Fiscal Year 2024 Results on Aug 29, 2024

Price target increased by 18% to AU$30.32

Clinuvel Pharmaceuticals Limited Announces Change of Company Secretary

CLINUVEL Announces A Novel Clinical Program

Price target decreased by 7.4% to AU$25.01

First half 2024 earnings released: EPS: AU$0.22 (vs AU$0.23 in 1H 2023)

Clinuvel Pharmaceuticals Limited to Report First Half, 2024 Results on Feb 22, 2024

Price target increased by 13% to AU$31.12

Price target decreased by 7.2% to AU$27.50

Clinuvel Pharmaceuticals Limited Announces Board Changes

Clinuvel Pharmaceuticals Limited, Annual General Meeting, Oct 31, 2023

Clinuvel Pharmaceuticals Limited Announces Dividend for the Full Year Ended June 30, 2023, Payable on September 20, 2023

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Clinuvel Pharmaceuticals Limited to Report Fiscal Year 2023 Results on Aug 29, 2023

If EPS Growth Is Important To You, Clinuvel Pharmaceuticals (ASX:CUV) Presents An Opportunity

Calculating The Intrinsic Value Of Clinuvel Pharmaceuticals Limited (ASX:CUV)

Is Now The Time To Put Clinuvel Pharmaceuticals (ASX:CUV) On Your Watchlist?

Estimating The Intrinsic Value Of Clinuvel Pharmaceuticals Limited (ASX:CUV)

Investor sentiment deteriorates as stock falls 20%

Now 22% undervalued

First half 2023 earnings released: EPS: AU$0.23 (vs AU$0.12 in 1H 2022)

Clinuvel Pharmaceuticals Ltd Announces the Completion of Manufacture of the First cGMP Batch of PRÉNUMBRA® Instant

Clinuvel Pharmaceuticals Limited Announces First Positive Results from Study Evaluating the Protective Effects of Afamelanotide on Skin Exposed to Ultraviolet Radiation

Price target increased by 11% to AU$28.94

Clinuvel Pharmaceuticals Limited Announces Neuracthel Manufacturing Processes Advance

Clinuvel Pharmaceuticals Limited Shares the First Results of Phase II Study Evaluating Afamelanotide in Patients with Xeroderma Pigmentosum

An Intrinsic Calculation For Clinuvel Pharmaceuticals Limited (ASX:CUV) Suggests It's 41% Undervalued

No independent directors

Increases to Clinuvel Pharmaceuticals Limited's (ASX:CUV) CEO Compensation Might Cool off for now

Clinuvel Pharmaceuticals Limited Announces Enrollment of First Patient in New Clinical Study CUV104

Investor sentiment improved over the past week

Clinuvel Pharmaceuticals Limited, Annual General Meeting, Oct 26, 2022

Full year 2022 earnings: EPS in line with expectations, revenues disappoint

Clinuvel Pharmaceuticals Limited Announces Dividend for the Full Year Ended June 30, 2022, Payable on September 21, 2022

Now 20% undervalued

Investor sentiment improved over the past week

Is Clinuvel Pharmaceuticals Limited (ASX:CUV) Trading At A 21% Discount?

CLINUVEL PHARMACEUTICALS LIMITED Intends to Evaluate its Drug Candidate PRÉNUMBRA Instant (Afamelanotide) as A Treatment for Patients Diagnosed with Arterial Ischaemic Stroke (AIS) in its Next Clinical Trial (CUV803)

Non-Executive Director recently sold AU$356k worth of stock

CLINUVEL Progresses CUV104 Vitiligo Study

CLINUVEL Releases Positive Final Results of the Open Label Pilot Study (CUV801) in Arterial Ischemic Stroke

No independent directors

Clinuvel Pharmaceuticals Ltd Appoints Andrew Likierman as New Non-Executive Director

Clinuvel Pharmaceuticals Limited Announces First XP-V Patient Treated in Third CUV DNA Repair Study

CEO, MD & Director recently sold AU$1.1m worth of stock

Now 22% undervalued after recent price drop

Clinuvel Pharmaceuticals Limited (ASX:CUV) Shares Could Be 27% Below Their Intrinsic Value Estimate

First half 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target decreased to AU$27.32

Investor sentiment deteriorated over the past week

Clinuvel Pharmaceuticals Limited Completes Enrolment in CUV801 Stroke Study

Does Clinuvel Pharmaceuticals (ASX:CUV) Deserve A Spot On Your Watchlist?

This Is The Reason Why We Think Clinuvel Pharmaceuticals Limited's (ASX:CUV) CEO Might Be Underpaid

A Look At The Fair Value Of Clinuvel Pharmaceuticals Limited (ASX:CUV)

Full year 2021 earnings released: EPS AU$0.50 (vs AU$0.31 in FY 2020)

Investor sentiment improved over the past week

Price target increased to AU$33.92

Here's Why I Think Clinuvel Pharmaceuticals (ASX:CUV) Might Deserve Your Attention Today

CEO, MD & Director recently sold AU$3.7m worth of stock

Non-Executive Director recently sold AU$692k worth of stock

Clinuvel Pharmaceuticals Limited Announces First Stroke Patient Treated with Afamelanotide

CEO, MD & Director recently sold AU$3.1m worth of stock

With EPS Growth And More, Clinuvel Pharmaceuticals (ASX:CUV) Is Interesting

Have Insiders Sold Clinuvel Pharmaceuticals Limited (ASX:CUV) Shares Recently?